A Bidirectional Observational Clinical Study of NAIC in the Treatment of Tumor Regression Patterns in LA-OSCC and LA-OPSCC
Condition(s) studied
Study summary
A prospective collection of 35 cases was conducted at Zhujiang Hospital of Southern Medical University. Patients diagnosed with locally advanced oral squamous cell carcinoma (LA-OSCC) or locally advanced oropharyngeal squamous cell carcinoma (LA-OPSCC) from April 2023 onward, who received two cycles of neoadjuvant immunochemotherapy (tislelizumab + paclitaxel + cisplatin/carboplatin) at our institution, were included. The study analyzed treatment safety, efficacy, tumor regression patterns, 2-year progression-free survival (PFS), and 5-year overall survival (OS) rates.
Eligibility
Primary outcome measure(s)
- 0bjective Response Rate — 8 weeks
According to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. it isdefined as the proportion of patients who achieved Complete Response (CR) or Partial Response(PR).Complete Response (CR) was defined as disappearance of all target lesions. PartialResponse (PR) was defined as \>=30% decrease in the sum of the longest diameter of targetlesions.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Department of Stomatology, Zhujiang Hospital, Southern Medical University,Guangzhou, Guangdong | Guangzhou | Guangdong | Recruiting |
More Zhujiang Hospital trials in China
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07133958 on ClinicalTrials.gov ↗ ← All trials in China